FR3106830B1 - Anticorps anti-protéine G alpha - Google Patents
Anticorps anti-protéine G alpha Download PDFInfo
- Publication number
- FR3106830B1 FR3106830B1 FR2000923A FR2000923A FR3106830B1 FR 3106830 B1 FR3106830 B1 FR 3106830B1 FR 2000923 A FR2000923 A FR 2000923A FR 2000923 A FR2000923 A FR 2000923A FR 3106830 B1 FR3106830 B1 FR 3106830B1
- Authority
- FR
- France
- Prior art keywords
- antibody
- nucleic acid
- protein
- alpha antibody
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000007523 nucleic acids Chemical group 0.000 abstract 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- 239000013598 vector Substances 0.000 abstract 2
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 230000006303 immediate early viral mRNA transcription Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
- G01N33/5735—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes co-enzymes or co-factors, e.g. NAD, ATP
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4719—G-proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Anticorps anti-protéine G alpha L’invention concerne des anticorps ou fragment d’anticorps capable de se lier à la protéine G alpha, des séquence d’acides nucléiques codant pour l’anticorps, des vecteurs comprenant la séquence d’acides nucléiques, des cellules comprenant le vecteur ou la séquence d’acides nucléiques et une trousse de réactifs comprenant (i) l’anticorps ou le fragment d’anticorps ou la composition et (ii) une source de GTP marqué avec un membre d’un couple de partenaires de RET.
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR2000923A FR3106830B1 (fr) | 2020-01-30 | 2020-01-30 | Anticorps anti-protéine G alpha |
PCT/FR2021/050164 WO2021152266A1 (fr) | 2020-01-30 | 2021-01-29 | Anticorps anti-proteine g alpha |
JP2022546606A JP2023511770A (ja) | 2020-01-30 | 2021-01-29 | 抗Gタンパク質α抗体 |
CN202180026754.2A CN115397858A (zh) | 2020-01-30 | 2021-01-29 | 抗G蛋白α抗体 |
US17/796,375 US20230091315A1 (en) | 2020-01-30 | 2021-01-29 | Anti-g-protein alpha antibody |
EP21707328.7A EP4097133A1 (fr) | 2020-01-30 | 2021-01-29 | Anticorps anti-proteine g alpha |
CA3166591A CA3166591A1 (fr) | 2020-01-30 | 2021-01-29 | Anticorps anti-proteine g alpha |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR2000923 | 2020-01-30 | ||
FR2000923A FR3106830B1 (fr) | 2020-01-30 | 2020-01-30 | Anticorps anti-protéine G alpha |
Publications (2)
Publication Number | Publication Date |
---|---|
FR3106830A1 FR3106830A1 (fr) | 2021-08-06 |
FR3106830B1 true FR3106830B1 (fr) | 2022-02-11 |
Family
ID=70918550
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR2000923A Active FR3106830B1 (fr) | 2020-01-30 | 2020-01-30 | Anticorps anti-protéine G alpha |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230091315A1 (fr) |
EP (1) | EP4097133A1 (fr) |
JP (1) | JP2023511770A (fr) |
CN (1) | CN115397858A (fr) |
CA (1) | CA3166591A1 (fr) |
FR (1) | FR3106830B1 (fr) |
WO (1) | WO2021152266A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3069644A1 (fr) * | 2017-07-28 | 2019-02-01 | Cisbio Bioassays | Methode pour mesurer la modulation de l'activation d'un recepteur couple a une proteine g |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107857810A (zh) | 2011-06-21 | 2018-03-30 | 非营利性组织佛兰芒综合大学生物技术研究所 | 针对gpcr:g蛋白复合物的结合结构域及来自其的用途 |
KR20160020552A (ko) * | 2013-06-17 | 2016-02-23 | 슈 생-쥐스땡 | 척추측만증 및 척추측만증 진행에 대한 마커로서 Gi 단백질 인산화, 척추측만 개체에서 GiPCR 신호전달을 증가시키는 방법 |
FR3069644A1 (fr) * | 2017-07-28 | 2019-02-01 | Cisbio Bioassays | Methode pour mesurer la modulation de l'activation d'un recepteur couple a une proteine g |
-
2020
- 2020-01-30 FR FR2000923A patent/FR3106830B1/fr active Active
-
2021
- 2021-01-29 CA CA3166591A patent/CA3166591A1/fr active Pending
- 2021-01-29 JP JP2022546606A patent/JP2023511770A/ja active Pending
- 2021-01-29 US US17/796,375 patent/US20230091315A1/en active Pending
- 2021-01-29 CN CN202180026754.2A patent/CN115397858A/zh active Pending
- 2021-01-29 WO PCT/FR2021/050164 patent/WO2021152266A1/fr unknown
- 2021-01-29 EP EP21707328.7A patent/EP4097133A1/fr active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3166591A1 (fr) | 2021-08-05 |
WO2021152266A1 (fr) | 2021-08-05 |
JP2023511770A (ja) | 2023-03-22 |
EP4097133A1 (fr) | 2022-12-07 |
FR3106830A1 (fr) | 2021-08-06 |
US20230091315A1 (en) | 2023-03-23 |
CN115397858A (zh) | 2022-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hino et al. | Protein photo-cross-linking in mammalian cells by site-specific incorporation of a photoreactive amino acid | |
CY1118462T1 (el) | Μονοκλωνικο αντισωμα κατα της πρωτεϊνης συνδεσης οστεοπροτεγερινης | |
Singh et al. | Characterization of protein cross-links via mass spectrometry and an open-modification search strategy | |
Tsai et al. | Mass spectrometry-based strategies for protein disulfide bond identification | |
CY1111283T1 (el) | Μορια με παρατεταμενες ημι-περιοδους ζωης, συνθεσεις και χρησεις εξ αυτων | |
BRPI0308585B8 (pt) | anticorpo isolado ou fragmento de ligação a antígeno do mesmo que se liga à alfavbeta6, composição, método de detecção in vitro de alfavbeta6 e construção de dna | |
UY38803A (es) | Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y usos de las mismas | |
NO20062886L (no) | IL-23 og dens reseptor, beslektede reagenser og fremgangsmater | |
CY1110877T1 (el) | Αλλαγη των συγγενειων συνδεσης me fcrn ή των ημιζωων ορου αντισωματων με μεταλλαξιγενεση | |
FR3034430B1 (fr) | Lignee cellulaire surexprimant l'antigene cd303 humain | |
FR3106830B1 (fr) | Anticorps anti-protéine G alpha | |
Nie et al. | Deep-dive targeted quantification for ultrasensitive analysis of proteins in nondepleted human blood plasma/serum and tissues | |
AU2002357779A8 (en) | Identification of high affinity molecules by limited dilution screening | |
Kuznetsova et al. | Modification of cysteine residues for mass spectrometry-based proteomic analysis: facts and artifacts | |
Pedersen et al. | A combined prediction strategy increases identification of peptides bound with high affinity and stability to porcine MHC class I molecules SLA-1* 04: 01, SLA-2* 04: 01, and SLA-3* 04: 01 | |
Mullen et al. | Development of ‘Redox Arrays’ for identifying novel glutathionylated proteins in the secretome | |
São Pedro et al. | Minimizing the Influence of Fluorescent Tags on IgG Partition in PEG–Salt Aqueous Two‐Phase Systems for Rapid Screening Applications | |
Vallée et al. | Ready display of antigenic peptides in a protein ‘mimogen’ | |
Storbeck et al. | Cytochrome b5 forms homomeric complexes in living cells | |
BR112023019458A2 (pt) | Proteínas que compreendem domínios de ligação ao antígeno de cd3 e usos dos mesmos | |
Solis et al. | Identification of protease cleavage sites and substrates in cancer by carboxy-TAILS (C-TAILS) | |
MX2022014938A (es) | Proteínas que comprenden dominios de unión al antígeno de cd3 y usos de éstas. | |
JP6624755B2 (ja) | プロテインタグ、タグ化タンパク質及びタンパク質精製方法 | |
Omali et al. | Quantification of protein deposits on silicone hydrogel materials using stable-isotopic labeling and multiple reaction monitoring | |
Pedroza-Díaz et al. | Proteomic analysis of cerebrospinal fluid: A search for biomarkers of neuropsychiatric systemic lupus erythematosus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PLFP | Fee payment |
Year of fee payment: 2 |
|
PLSC | Publication of the preliminary search report |
Effective date: 20210806 |
|
PLFP | Fee payment |
Year of fee payment: 3 |
|
PLFP | Fee payment |
Year of fee payment: 4 |
|
PLFP | Fee payment |
Year of fee payment: 5 |